Factors such as increase in awareness of hypercholesterolemia and cardiovascular diseases, changing lifestyle pattern, increase number of obese population and growing geriatric population are driving the growth of hypercholesterolemia drugs market globally.
The report titled “Hypercholesterolemia Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall hypercholesterolemia drugs market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug class and different geographical regions.
Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hypercholesterolemia drugs market. Tools such as market positioning of key players, pipeline analysis and attractive investment proposition provide the readers with insights on the competitive scenario of the global hypercholesterolemia drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global hypercholesterolemia drugs market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global hypercholesterolemia drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Hypercholesterolemia also known as high cholesterol, it is characterized by presence of high levels of cholesterol in the body that increases a risk of developing heart attack and stroke. Some factors such as changing lifestyle pattern, rising healthcare awareness, increase in number of obese population, growing incidence of hypercholesterolemia related diseases, growing awareness about cardiovascular diseases and rising geriatric population are primarily driving the growth of hypercholesterolemia drugs market globally. For the purpose of the study hypercholesterolemia drugs market is segmented on the basis of drug class such as HMG-CoA reductase inhibitors, bile acid sequestrants, fibric acid derivatives, cholesterol absorption inhibitors and others. It is studied that, among the considered market segment, statins is major revenue contributing segment because it’s recommended use in management of hypercholesterolemia due to their safety and effectiveness. Furthermore statins competitively inhibit HMG-CoA reductase which responsible for the production of cholesterol, moreover statins are involves in decreasing level of LDL cholesterol and increasing level of HDL cholesterol and thus most preferred in the hypercholesterolemia market.
Among the considered market segment, North America dominated the global Hypercholesterolemia market and growth was primarily driven by United States. Some factors such as sedentary lifestyle pattern, higher cost of medication, large number of target population, increasing risk of cardiovascular diseases and higher treatment awareness are prime factors that are assisting the market growth in North America. According to Centers for Disease Control and Prevention (CDC) more than 73.5 million adults (31.7%) in United States have high low-density lipoprotein. Nearly 31 million adult Americans have a total cholesterol level greater than 240 mg/dL. According to World Health Organization (WHO), over 50% of adults had raised total cholesterol in high-income countries; more than double the level of the low-income countries. It is estimated that Asia Pacific will show highest growth during forecast period due to rising healthcare awareness and changing lifestyle pattern would influence the market growth of hypercholesterolemia drugs.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hypercholesterolemia Drugs market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Drugs Class
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
